Company intelligence / Profile preview

Climb Bio

Wellesley, Massachusetts, United Statesclimbbio.com ↗

Ownership: Public · CLYM
Development stage: Phase 1

Overview

Lead candidate budoprutug is in Phase 2 for Primary Membranous Nephropathy and Phase 1 for Immune Thrombocytopenia and Systemic Lupus Erythematosus. CLYM116 is in preclinical development for IgA Nephropathy.

Therapeutic areas: ImmunologyNephrologyHematology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

2 assets

budoprutug

Phase 1

Indications: Membranous Nephropathy, Immune Thrombocytopenia, Systemic Lupus Erythematosus

1 more asset in the full pipeline.

Request access →

Partnerships

Beijing Mabworks Biotech

Financials

Market cap: $910.5M
Total revenue: $0
Enterprise value: $728.7M

Beyond the preview

Go deeper on Climb Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Climb Bio.

Explore the full profile